US Corporate Distress Financial Stress SEC Filings — March 30, 2026

30-03-2026

Ingevity Corporation, along with Ingevity Holdings SRL and Ingevity UK Ltd, entered into a Second Amendment and Restatement Agreement dated March 26, 2026, amending their existing credit agreement to establish new Revolving Commitments totaling $750 million, with proceeds used to repay all outstanding revolving loans under the prior facility. The transaction involves JPMorgan Chase Bank, N.A. as Administrative Agent and other lenders, with effectiveness subject to standard conditions including legal opinions, solvency certificates, and repayment of prior obligations. No comparative financial metrics or performance declines are disclosed in the filing.

• ·Existing Credit Agreement originally dated June 23, 2022
• ·Amendment Arrangers: JPMorgan Chase Bank, N.A., BofA Securities, Inc., Citizens Bank, N.A., PNC Bank, National Association, TD Securities (USA) LLC
• ·Legal opinions required from Wachtell, Lipton, Rosen & Katz, McGuireWoods LLP, Loyens & Loeff CVBA, NautaDutilh BV/SRL, Cahill Gordon & Reindel (UK) LLP
• ·Engagement Letter dated February 19, 2026

30-03-2026

Vine Hill Capital Investment Corp. shareholders overwhelmingly approved the business combination with CoinShares International Limited at the March 27, 2026 extraordinary general meeting, with 92.6% of votes cast in favor of the Business Combination Proposal (22,095,264 For vs. 1,764,990 Against). The company notified Nasdaq on March 24, 2026, of its intent to voluntarily delist its units (VCICU), Class A ordinary shares (VCIC), and warrants (VCICW) following the merger closing, with Odysseus Holdings Limited's ordinary shares and warrants expected to list on Nasdaq thereafter. The transaction is anticipated to close on March 31, 2026, subject to customary conditions including Jersey regulatory approvals.

• ·Shareholder Meeting quorum: holders of 16,526,920 Class A and 7,333,334 Class B ordinary shares present, representing 81.342% of voting power as of record date March 2, 2026.
• ·All Shareholder Proposals approved, including SPAC Merger Proposal (identical vote to Business Combination), Organizational Document Proposals (some with 150,000 abstentions), and NTA Proposal (23,685,207 For, 25,047 Against, 150,000 Abstain).
• ·Registration Statement on Form F-4 (No. 333-293885) declared effective March 16, 2026; Proxy Statement mailed same day.
• ·Merger structure: SPAC merges into SPAC Merger Sub (Odysseus (Cayman) Limited) on March 30, 2026, followed by scheme of arrangement acquiring CoinShares on March 31, 2026.

30-03-2026

DarioHealth Corp. entered into a Sales Agreement with A.G.P./Alliance Global Partners on March 30, 2026, enabling the potential issuance and sale of up to $20,000,000 of common stock via an at-the-market offering program. Net proceeds may fund commercial and marketing activities, R&D, M&A, repayment of debt to Callodine Commercial Finance, LLC, and general working capital. The Agent earns a 3.00% commission on gross proceeds, with reimbursements capped at $35,000 initially plus additional quarterly and refresh fees.

• ·Sales Agreement uses effective Form S-3 shelf registration (File No. 333-294454), filed March 19, 2026, effective March 27, 2026.
• ·Offering terminates upon full share sales, registration expiration, or party termination.
• ·Common stock: par value $0.0001 per share, traded as DRIO on Nasdaq Capital Market.

30-03-2026

OnKure Therapeutics entered into a securities purchase agreement on March 27, 2026, for a private placement expected to generate approximately $150.0 million in gross proceeds through the sale of 26,713,636 shares of Class A common stock at $4.15 per share and pre-funded warrants to purchase 9,430,959 shares at $4.1499 per underlying share, with closing anticipated on March 31, 2026. The company elected Dr. Liam Ratcliffe, affiliated with lead investor AI Biotechnology LLC, as a Class I director effective upon closing, and plans to use proceeds for preclinical/clinical development of next-generation PI3Kα inhibitors OKI-345 and OKI-355, with IND submissions targeted for H1 2027. However, despite progress in the PIKture-01 trial (completed dose escalations with n=38 single-agent and n=33 + fulvestrant), the company will not pursue further independent clinical development of OKI-219.

• ·Private Placement closing subject to customary conditions on March 31, 2026.
• ·180-day lock-up for executives/directors and Company on share issuances post-Closing.
• ·Registration Statement to be filed within 30 days after Closing, with effectiveness targets of 90-120 days.
• ·Pre-Funded Warrants exercisable at $0.0001 per share, no expiration until fully exercised.
• ·Phase 2 dose evaluation in PIKture-01 (OKI-219 triplets) to complete in 2026; mature data presentation by year-end.
• ·Dr. Ratcliffe to receive standard non-employee director compensation per Company policy.

30-03-2026

On March 27, 2026, Dyadic International, Inc. received a Nasdaq deficiency notice for failing to comply with Continued Listing Rule 5550(b), requiring at least $2.5 million in stockholders’ equity, $35 million in market value of listed securities, or $500,000 in net income from continuing operations; the notice has no immediate listing effect but mandates a compliance plan by May 11, 2026, with potential extension to September 23, 2026. The company plans to pursue compliance, likely via the equity threshold, amid ongoing non-compliance with the $1.00 minimum bid price rule (deadline June 17, 2026), either of which could lead to delisting if unresolved.

• ·The deficiency notice has no immediate effect on the listing of DYAI common stock on Nasdaq Capital Market.
• ·Company remains out of compliance with separate minimum bid price requirement, which is unrelated to the new notice.

30-03-2026

Our Bond, Inc. (OBAI) entered into Amendment No. 2 to its Securities Purchase Agreement (Equity Line SPA) with Ascent Partners Fund LLC on March 29, 2026, amending terms for Regular Closings (max $1,000,000 or 100% of average daily traded value over prior 10 trading days) and Expanded Closings (up to $5,000,000 under specific volume and price conditions or if average daily traded value exceeds $4,000,000). The amendment allows advance notices anytime during trading days, multiple per day, and includes extended hours trading in key definitions. No financial performance metrics or period comparisons are reported.

• ·Expanded Closing advance notice requires trading volume exceeding 3 times the average daily volume over the prior 10 trading days.
• ·VWAP, daily traded value, and volume definitions now include extended hours trading.
• ·Equity Line SPA effective date clarified as the registration statement effective date for Ascent’s resale of shares.

30-03-2026

Amphenol Corporation entered into an Indenture dated March 30, 2026, with Amphenol Technologies Holding GmbH as issuer, Amphenol Corporation as guarantor, and U.S. Bank Trust Company, National Association as trustee, for the issuance of Notes. This agreement creates a direct financial obligation under Item 2.03. The filing incorporates an Officers’ Certificate establishing the Notes and lists various exhibits including legal opinions.

• ·Exhibits include: 4.1 (Indenture), 4.2 (Officers’ Certificate), 4.3 (Form of Global Note), 5.1 (Opinion of Latham & Watkins LLP, New York), 5.2 (Opinion of Latham & Watkins LLP, Frankfurt), 23.1 and 23.2 (Consents), 104 (XBRL Cover Page)
• ·Incorporated by reference into Registration Statement No. 333-293923

30-03-2026

Volato Group, Inc. entered into an ATM Sales Agreement with Curvature Securities, LLC to offer and sell up to $3,700,000 of Class A Common Stock at-the-market. The company provided an update on its pending merger with M2i Global, Inc., where M2i shareholders are expected to receive approximately 85% ownership of the combined company (via ~119.2M shares), resulting in significant dilution for existing Volato shareholders who will hold ~15%. The merger faces risks including stockholder approvals, integration challenges, operational disruptions, and potential failure to realize strategic benefits.

• ·ATM sales made via methods permitted under Rule 415, including directly on NYSE American LLC.
• ·Merger Agreement originally dated July 28, 2025; shelf registration on Form S-3 (File No. 333-290219) effective September 30, 2025.
• ·Company plans to seek stockholder approval for potential reverse stock split to meet NYSE American listing requirements.
• ·Merger closing subject to M2i Global and Volato stockholder approvals, with risks of delays, termination, or adverse business impacts.

30-03-2026

Nexstar Media Group, Inc. and Nexstar Media Inc. entered into Amendment No. 9 to their Credit Agreement dated March 25, 2026, effective on the same date, under which Bank of America, N.A., as Term B-7 Lender, provides new Term B-7 Loans in an aggregate principal amount of $1,750,000,000. The proceeds are used to fully repay outstanding Term B-6 Loans (Term B-6 Refinancing) and pay fees and expenses associated with the transaction. The amendment includes standard conditions precedent, representations, and reaffirmations of loan documents, with no reported changes in financial performance metrics.

• ·Amendment executed by Borrower (Nexstar Media Inc.), Nexstar Media Group, Inc., other Loan Parties, Administrative Agent (Bank of America, N.A.), and Term B-7 Lender.
• ·Ninth Amendment Effective Date: March 25, 2026.
• ·SEC 8-K filing date: March 30, 2026, covering Items 1.01, 1.02, 2.03, 9.01.

30-03-2026

AB Private Credit Investors Corp and multiple affiliated Borrowers and General Partners entered into the Eighteenth Amendment to their Revolving Credit Agreement originally dated June 14, 2019, with HSBC Bank USA, National Association as Administrative Agent, effective as of March 23, 2026. The amendment modifies certain sections and schedules of the Credit Agreement as set forth in Annex A (not provided), subject to conditions including execution, beneficial ownership certifications, and payment of fees. All parties reaffirmed the validity of liens, resolutions, and obligations under the Loan Documents, with representations that no Potential Default or Event of Default exists.

• ·Original Revolving Credit Agreement dated June 14, 2019.
• ·This is the eighteenth amendment; prior amendments listed from December 23, 2020 through December 8, 2025.
• ·Governing law: State of New York.
• ·SEC Filing Date: March 30, 2026; Items: 1.01, 2.03, 9.01.

30-03-2026

NaturalShrimp Inc (SHMP) filed an 8-K on March 30, 2026, under Items 1.01 (Material Definitive Agreement), 3.02 (Unregistered Sales of Equity Securities), 5.01 (Changes in Control), 5.02 (Director/Officer Changes), and 9.01 (Financial Statements and Exhibits), indicating significant corporate governance and control shifts. The filing attaches Exhibit 3.1, likely an amendment to the Articles of Incorporation or Bylaws. No financial metrics or performance data were disclosed.

• ·Filing includes Items: 1.01, 3.02, 5.01, 5.02, 9.01
• ·Exhibit 3.1 attached (likely governance amendment)

30-03-2026

Connect Biopharma announced positive topline results from its Phase 1 study (CBP-201-105) of intravenous rademikibart (300 mg, 2-minute IV push) in asthma and COPD patients, showing rapid FEV1 improvements of ≥200 mL in many patients as early as 15 minutes post-dosing, with mean improvements of ~200-400 mL maintained through Day 29 versus placebo decline. The treatment was generally well-tolerated with no serious adverse events, no severe AEs, and no discontinuations. Ongoing Phase 2 Seabreeze STAT studies expect topline data in mid-2026.

• ·Mean baseline FEV1: 1.9 L (asthma), 1.55 L (COPD)
• ·Randomized 4:1 rademikibart:placebo
• ·Exclusive license to Simcere for rademikibart in Greater China with royalties up to low double-digits
• ·Conference call and webcast on March 30, 2026 at 8:00 a.m. ET

30-03-2026

Spire Inc. announced the sale of its gas marketing business, Spire Marketing Inc., to Boardwalk Pipelines, LP for $215 million in cash, expected to close in Q3 FY2026, to sharpen focus on regulated utility operations, improve risk profile, and fund the Piedmont Natural Gas Tennessee acquisition and corporate purposes. The company reaffirmed FY2026 adjusted EPS guidance of $5.25–$5.45 and long-term EPS growth of 5-7% from the original FY2027 midpoint of $5.75. However, updated FY2027 adjusted EPS guidance was lowered to $5.40–$5.60 from the prior $5.65–$5.85.

• ·Transaction subject to regulatory approvals, customary closing conditions, and HSR Antitrust waiting period.
• ·FY2026 adjusted EPS guidance of $5.25–$5.45 affirmed, reflecting full-year earnings from Spire Marketing and storage prior to sales.
• ·Piedmont Natural Gas Tennessee acquisition expected to close in Q1 calendar 2026.
• ·Update on potential sale of natural gas storage facilities expected by Q2 FY2026 earnings call in May 2026.

30-03-2026

Capstone Green Energy Holdings, Inc. (CGEH) announced a $112.5 million strategic investment led by Monarch Alternative Capital LP, consisting of $80 million in new senior convertible preferred stock and $15 million in common stock from Monarch, plus a $17.5 million PIPE from existing investors. $85 million of proceeds will redeem legacy preferred equity held by a Goldman Sachs affiliate, simplifying the capital structure and making Capstone Green Energy LLC a wholly owned subsidiary. Remaining funds support general working capital and growth initiatives, including AI data center expansion, with board expansion to seven members including two Monarch appointees and a path to national exchange listing.

• ·Preferred Stock convertible at $5.00 per share, 5.00% PIK dividend, senior ranking, mandatory conversion if stock trades above $15.00 for 20 of 30 days.
• ·PIPE priced at $4.50 per share.
• ·45-day lock-up for Company directors and executives.
• ·Resale registration statement to be filed within 30 days of closing.
• ·Initial listing application for national exchange within 12 months.
• ·Expected closing on or about March 31, 2026.

30-03-2026

Atmos Energy Corporation extended the maturity of its $1.5 billion senior unsecured Three Year Credit Facility by one year to March 28, 2029, and its $1.5 billion senior unsecured Five Year Credit Facility by one year to March 28, 2031, both effective as of March 27, 2026. These extensions, made pursuant to Section 2.23 of each Revolving Credit Agreement originally entered on March 28, 2024, maintain the company's total revolving credit capacity at $3.0 billion without other reported changes.

• ·Extensions allow for up to two one-year extensions total per facility
• ·Facilities administered by Crédit Agricole as Administrative Agent

30-03-2026

Kirby Corporation entered into an Amended and Restated Credit Agreement on March 26, 2026, amending and restating its prior credit agreement dated July 29, 2022, with JPMorgan Chase Bank, N.A. as administrative agent and a syndicate of lenders including Bank of America, N.A., PNC Bank, National Association, Wells Fargo Bank, National Association as syndication agents, and BOKF, N.A. dba Bank of Texas as documentation agent. The agreement governs revolving loans, swingline loans, and letters of credit, with applicable margins for interest rates and fees determined by the company's S&P, Moody's, and/or Fitch ratings, ranging from 0.00%-0.500% over ABR and 0.875%-1.500% over Term SOFR/RFR, plus commitment fees of 0.070%-0.200%. No borrowings or specific facility size are detailed in the filing.

• ·Prior agreement dated July 29, 2022
• ·Pricing levels based on S&P/Moody’s/Fitch ratings (Levels I to V: A-/A3/A- or better to BB+/Ba1/BB+ or worse)
• ·Schedules include Commitments (2.01), Existing Letters of Credit (1.01), Consolidated Subsidiaries (3.01)

30-03-2026

Ares Commercial Real Estate Corp (ACRE), as guarantor, along with its subsidiaries ACRC Lender MS LLC and ACRC Lender MS II LLC as sellers, entered into the Eighth Amendment to the Master Repurchase and Securities Contract with Morgan Stanley Bank, N.A. as buyer, dated March 24, 2026. The amendment sets the Facility Amount at $350,000,000, establishes a Preapproved Accordion Amount of $400,000,000 with provisions for further increases subject to conditions, and extends the Initial Facility Termination Date to July 16, 2029. Seller paid an Upsize Fee of $78,082.19, with representations confirming no existing Defaults, Events of Default, or Material Adverse Effects.

• ·Original Repurchase Agreement dated January 16, 2020, with Seller II joinder via Omnibus Amendment dated December 23, 2024.
• ·Effectiveness conditions include executed amendment, payment of Buyer's costs and expenses, Officer's Certificate, good standing certificates, and legal opinions within 10 Business Days.

30-03-2026

On March 24, 2026, the Nasdaq Listing Council modified a prior delisting decision by a Nasdaq Hearings Panel, providing Triller Group Inc. with conditional reinstatement of its Nasdaq listing for Common Stock (ILLR) and Warrants (ILLRW). Trading will resume the day after filing the overdue 2025 Form 10-K by March 31, 2026 (or via SEC Rule 12b-25 extension), but failure to file will trigger immediate delisting without appeal. The company has cured prior delinquencies by filing its 2024 Form 10-K and Q1-Q3 2025 Forms 10-Q in late January 2026, though trading remains suspended since December 30, 2025.

• ·Original delisting notices issued October 14, 2025, and November 17, 2025, due to non-compliance with Nasdaq Listing Rule 5250(c)(1).
• ·Nasdaq Hearings Panel hearing held November 25, 2025; extension request denied December 26, 2025.
• ·SEC denied company's emergency stay application on December 31, 2025.
• ·Company appealed to Listing Council on January 9, 2026.

30-03-2026

Lunai Bioworks, Inc. (NASDAQ: LNAI) executed a binding $20 million strategic transaction to acquire blood-brain barrier (BBB) delivery technology and CNS Alzheimer’s drug assets from the Clemann Group, SAS or its assignee. The deal is structured as Series B Convertible Preferred stock at a fixed $1.50 per share conversion price, subject to a 19.9% beneficial ownership limitation, with no variable pricing or reset provisions. This acquisition enhances Lunai’s CNS Alzheimer’s pipeline by enabling effective brain delivery of therapeutics and expands potential applications to broader CNS disorders.

• ·Transaction announced on March 26, 2026; SEC filing dated March 30, 2026
• ·Fixed conversion price of $1.50 per share with 19.9% beneficial ownership limitation
• ·Platform targets acetylcholinesterase modulation pathways for neurological diseases

30-03-2026

Liberty Energy Inc. (NYSE: LBRT) announced a proposed private offering of $450.0 million aggregate principal amount of convertible senior notes due 2032, with an option for initial purchasers to buy up to an additional $50.0 million. Proceeds will fund capped call transactions to mitigate dilution upon conversion and general corporate purposes. The offering includes potential market impacts from hedging activities by counterparties, which could affect the Class A Common Stock price positively or negatively.

• ·Notes mature on March 1, 2032; interest payable semiannually starting September 1, 2026
• ·Conversion possible under certain conditions prior to December 1, 2031, thereafter at any time until maturity
• ·Liberty may redeem notes for cash on or after March 1, 2029, if stock price >=130% of conversion price
• ·Offering to qualified institutional buyers under Rule 144A; not registered under Securities Act

30-03-2026

Precision Optics Corporation, Inc. (NASDAQ: POCI) announced on March 26, 2026, the commencement of an underwritten public offering of shares of its common stock (or equivalents), subject to market conditions with no assurance on completion, size, or terms. Lucid Capital Markets is acting as the sole book-running manager. The offering is pursuant to a shelf registration statement on Form S-3 (File No. 333-280047), filed June 7, 2024, amended June 11, 2024, and effective June 14, 2024.

• ·SEC filing date: March 30, 2026
• ·8-K Items: 1.01, 3.02, 8.01, 9.01
• ·Company address: 22 East Broadway, Gardner, Massachusetts 01440-3338
• ·Shelf registration File No.: 333-280047

30-03-2026

Expedia Group, Inc. entered into a new Credit Agreement dated March 27, 2026, with JPMorgan Chase Bank, N.A. as Administrative Agent and various lenders, providing for revolving loans, borrowings in US Dollars and Alternative Currencies (Euro, Sterling, Canadian Dollars, Australian Dollars), and letters of credit. The agreement includes commitments detailed in Schedule 2.01 (not specified in excerpt), with pricing tiers based on credit ratings from S&P, Moody's, and Fitch, featuring commitment fees of 10.0-25.0 basis points and Term Benchmark/RFR spreads of 100.0-175.0 basis points. No performance declines or flat metrics are mentioned, as this is a financing arrangement rather than operational results.

• ·Filing Date: March 30, 2026
• ·Alternative LC Currencies include Singapore Dollars and others acceptable to Administrative Agent and Issuing Bank
• ·Leverage Ratio covenant in Section 6.06
• ·Schedules include Commitments (2.01), Existing Letters of Credit (2.05A), Existing Indebtedness (6.01), Existing Liens (6.02)

30-03-2026

Star Equity Holdings, Inc.'s wholly owned subsidiary, Alliance Drilling Tools, LLC, closed the sale of its Texas property in Midland for $1.14 million and Utah property in Vernal for $0.55 million on March 27, 2026, pursuant to purchase agreements dated December 16, 2025. Simultaneously, ADT entered into 20-year triple net leasebacks for both properties, guaranteed by the company, under which ADT remains responsible for all rent and operating expenses. This completes two of three previously announced sale-leaseback transactions, following the Wyoming property closing on February 27, 2026.

• ·Lease terms commence March 27, 2026, and end on the 20th anniversary, with options for four additional five-year periods.
• ·Original purchase and sale agreements dated December 16, 2025, filed as Exhibits to Form 8-K on December 17, 2025.
• ·Custom Capital assigned its purchase rights to Alliance Texas and Utah, LLC immediately prior to closings.
• ·Wyoming property sale closed February 27, 2026, as previously reported.

30-03-2026

On March 24, 2026, NexPoint Diversified Real Estate Trust, through its indirect subsidiary NXDT Hospitality Holdco, LLC, entered into a Membership Interest Purchase Agreement to sell 100% of the membership interests in NHT Bradenton, LLC (owner of the Bradenton Hampton Inn & Suites property) to OSL Bradenton Downtown, LLC for approximately $26.3 million in cash, with the transaction closing on the same date. The net proceeds will be used for short-term liquidity needs. The buyer is deemed an affiliate of the Company's adviser NexPoint Real Estate Advisors X, L.P., and the agreement was reviewed and approved by the Company's Audit Committee in compliance with its Related Party Transaction Policy.

• ·Transaction subject to customary closing adjustments.
• ·MIPA contains customary representations, warranties, and covenants.

30-03-2026

On March 25, 2026, QuoteLab, LLC and QL Holdings LLC, subsidiaries of MediaAlpha, Inc., entered into an Amendment and Restatement Agreement amending their existing Credit Agreement, establishing a new $150 million five-year senior secured term loan facility to refinance prior term loans and support general corporate purposes, and a new $60 million five-year senior secured revolving credit facility. The facilities are guaranteed by Holdings and secured by substantially all assets of Holdings and the Borrower, with maturity on March 25, 2031, and term loan amortization beginning June 30, 2026. No performance declines or flat metrics are reported in this financing update.

• ·Borrowings bear interest at Term SOFR, Daily Simple SOFR, or Alternate Base Rate plus applicable margins based on consolidated total net leverage ratio.
• ·Term loans require prepayments from non-ordinary course asset sales, casualty, and condemnation events, subject to exceptions.
• ·Credit Agreement includes customary affirmative, negative, and financial covenants and default provisions.

30-03-2026

Invech Holdings, Inc. (IVHI) filed an 8-K on March 30, 2026, disclosing the adoption of Amended and Restated Bylaws effective March 27, 2026, under Items 1.01, 5.03, and 9.01. The bylaws establish the principal office in Nevada, govern stock certificates (including uncertificated shares), transfers, stockholder meetings (annual and special), quorum at one-third (1/3) of voting power, notice periods (10-60 days), and proxy validity (6 months). No financial metrics, operational changes, or performance data are mentioned.

• ·Stockholder meeting quorum: one-third (1/3) of voting power present in person or by proxy
• ·Meeting notice: not less than 10 days nor more than 60 days prior
• ·Proxy validity: not more than 6 months from execution
• ·Stock transfer books may be closed for up to 60 days; record date not more than 60 or less than 10 days prior to action

30-03-2026

Sky Quarry Inc. received a Nasdaq notice on March 24, 2026, of delisting determination due to prolonged non-compliance with the $1.00 minimum bid price rule under Nasdaq Listing Rule 5550(a)(2), with trading suspension scheduled for March 31, 2026. However, following a 1-for-8 reverse stock split on March 15, 2026, the company regained compliance by maintaining the minimum bid price for 10 consecutive business days, receiving a compliance notice on March 30, 2026, closing the matter. This resolution avoids delisting after prior non-compliance periods expiring in September 2025 and March 2026.

• ·Initial non-compliance notification: March 28, 2025
• ·First 180-day compliance period expired: September 24, 2025
• ·Second 180-day compliance period expired: March 23, 2026
• ·Reverse stock split effected: March 15, 2026
• ·Reverse split-adjusted trading began: March 16, 2026
• ·Delisting notice issued: March 24, 2026
• ·Compliance notice received: March 30, 2026
• ·Planned trading suspension: March 31, 2026 (averted)

30-03-2026

Apollo Global Management, Inc. issued $750,000,000 aggregate principal amount of 5.700% Senior Notes due 2036 on March 30, 2026, pursuant to an indenture with U.S. Bank Trust Company, National Association as trustee. The proceeds will be used for general corporate purposes, including the repurchase or repayment of $500,000,000 outstanding 4.400% Senior Notes due 2026 issued by Apollo Management Holdings, L.P. Interest on the new notes accrues at 5.700% per annum, payable semi-annually starting September 30, 2026, with maturity on March 30, 2036.

• ·Underwriting agreement dated March 25, 2026, with BofA Securities, Inc., Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC, and Morgan Stanley & Co. LLC as representatives.
• ·Indenture dated March 30, 2026; notes sold pursuant to Form S-3 registration statement (File No. 333-271275).
• ·Opinion of counsel from Paul, Weiss, Rifkind, Wharton & Garrison LLP filed as Exhibit 5.1.

30-03-2026

WisdomTree, Inc. issued $603.75 million in aggregate principal amount of 4.50% Convertible Senior Notes due 2031 pursuant to an Indenture dated March 30, 2026, generating approximately $591.2 million in net proceeds from the private offering to qualified institutional buyers. The notes are senior unsecured obligations ranking equal to the company's existing convertible notes due 2026, 2029, and 2030, with interest payable semiannually at 4.50% and maturity on October 1, 2031. Holders may convert under specified conditions at an initial rate of 46.3306 shares per $1,000 principal (approximately $21.58 per share), with no early redemption before April 6, 2028.

• ·Initial conversion rate: 46.3306 shares per $1,000 principal amount (approx. $21.58 per share); maximum conversion rate: 74.1282 shares per $1,000.
• ·Notes not redeemable before April 6, 2028; interest payments begin October 1, 2026.
• ·Purchase Agreement dated March 23, 2026.

30-03-2026

Aprea Therapeutics, Inc. (Nasdaq: APRE) announced an oversubscribed $30 million private placement financing led by Soleus Capital, with participation from Vestal Point Capital, Squadron Capital Management, existing investors, and insiders, expected to close on or about March 31, 2026. The offering includes pre-funded warrants and warrants to purchase approximately 37.2 million shares of common stock each, with gross proceeds intended for general corporate purposes, R&D, and expanding the ACESOT-1051 Phase 1 trial enrollment in uterine serous carcinoma (USC) and Cyclin E-overexpressing platinum-resistant ovarian cancer (PROC) patients. The proceeds are expected to extend the company's cash runway into Q1 2028, with dose escalation completion anticipated in Q2 2027.

• ·Warrants exercisable immediately upon issuance and expire on the earlier of December 31, 2029, or 30 days after pro rata exercise of corresponding Pre-Funded Warrant
• ·Company to file SEC registration statement for resale of securities
• ·Oppenheimer & Co. Inc. acting as lead placement agent; Maxim Group LLC as co-lead

30-03-2026

Compass Diversified (CODI) announced a definitive agreement to sell Sterno’s food service business to Archer Foodservice Partners for an enterprise value of $292.5 million, with the divested business generating $30.3 million in subsidiary adjusted EBITDA in 2025. Net proceeds will repay debt, reducing CODI's senior secured net leverage ratio below 1.0x and avoiding excess leverage fees beyond June 30, 2026. CODI will retain the higher-margin Rimports home fragrance business, which reported $28.1 million adjusted EBITDA in 2025.

• ·Transaction expected to close in May 2026, subject to customary closing conditions including regulatory approvals.
• ·Raymond James served as financial advisor to CODI; Brownstein Hyatt Farber Schreck, LLP as legal counsel.
• ·Sterno’s brand roots date back over 125 years.

30-03-2026

Rapid7, Inc. entered into a Nomination and Support Agreement with JANA Partners Management, LP on March 26, 2026, agreeing to nominate and support Kevin Galligan for election as a director at the 2026 annual meeting of stockholders on the same terms as other board nominees. JANA committed to voting its shares in favor of Galligan and the Company's specified directors (Corey E. Thomas, Marc Brown, Judy Bruner, Mike Burns, Benjamin Holzman, Wael Mohamed, J. Benjamin Nye, Thomas Schodorf, Reeny Sondhi) at the meeting. The agreement caps JANA's ownership at 19.9% without board consent and terminates on the earlier of 30 days prior to the 2027 director nomination advance notice period or January 8, 2027.

• ·Board approved JANA's acquisitions up to 19.9% ownership threshold to waive Delaware General Corporation Law Section 203 business combination restrictions.
• ·Agreement filed as Exhibit 10.1.

30-03-2026

CNH Industrial N.V. has obtained a 12-month extension on its €3.25 billion Revolving Credit Facility, originally dated April 19, 2024, shifting the First Extended Termination Date from April 19, 2030, to the Second Extended Termination Date of April 18, 2031. This second extension request was approved by the Banks, with Citibank Europe plc, UK Branch acting as Facility Agent. The extension maintains Total Commitments at €3.25 billion, bolstering the company's long-term liquidity without any reported changes to terms or costs.

• ·Original credit agreement dated 19 April 2024
• ·First extension to 19 April 2030
• ·Extension letter dated 26 March 2026
• ·SEC 8-K filing date: March 30, 2026

30-03-2026

Artelo Biosciences, Inc. (Nasdaq: ARTL) announced a $11.0 million private placement, entering definitive agreements for 3,188,407 shares of common stock (or pre-funded warrants) and warrants to purchase 6,376,814 shares at $3.45 per share, priced at-the-market under Nasdaq rules. The offering, led by H.C. Wainwright & Co., is expected to close on or about March 30, 2026, with gross proceeds for working capital, general corporate purposes, and bridge debt repayment; potential additional proceeds from warrant exercises total $20.4 million.

• ·Warrants exercisable at $3.20 per share upon issuance, expiring five and one-half years from resale registration statement effectiveness.
• ·Private placement under Section 4(a)(2) of Securities Act and Regulation D; resale registration statement to be filed.
• ·Announcement date: March 27, 2026; expected closing: on or about March 30, 2026.

30-03-2026

ECD Automotive Design, Inc. entered into additional senior secured convertible notes under its June 2025 SPA with its parent company (the Holder), issuing notes with $395,859.66 principal for a $360,326.85 purchase price, convertible into 116,429,312 shares at a $0.0034 floor price, subject to a 9.99% beneficial ownership limit. The notes mature on December 12, 2026, and the Holder's total outstanding principal to the Company is now $12,844,574 as part of the original up-to-$21,972,275.38 facility. No financial performance metrics were reported, but the low conversion price highlights significant potential dilution risk.

• ·Additional notes effective as of March 23, 2026, with exercise date March 24, 2026.
• ·Maturity date for additional notes: December 12, 2026, subject to Holder extension rights.
• ·Transaction exempt under Section 4(a)(2) and Rule 506 of Regulation D.

30-03-2026

agilon health, inc. amended its Amended and Restated Certificate of Incorporation via a Certificate of Amendment filed with the Delaware Secretary of State, effective March 30, 2025, to implement a 1-for-25 reverse stock split of its Common Stock. Each 25 shares outstanding immediately prior to the effective time will automatically convert into one share, with no fractional shares issued and cash payments made in lieu thereof based on aggregated and sold fractional shares by the transfer agent. The amendment does not alter the total authorized number of Common Stock shares.

• ·Corporation incorporated on April 21, 2017, under Delaware General Corporation Law
• ·Amendment affects Article FOURTH of the Certificate of Incorporation

30-03-2026

Village Farms International, Inc. (VFF) favorably amended and extended its loan with Farm Credit Canada (FCC), reducing the interest rate by 50 basis points to below 7.0% and extending the maturity by four years to February 3, 2031, on a current balance of US $15.4 million. All other material terms remain unchanged, reflecting the company's strengthening business position as noted by EVP and CFO Stephen Ruffini. The amendment underscores FCC's long-term support after 20 years of partnership.

• ·Asset portfolio spans over 7 million square feet of advanced greenhouse and indoor cultivation assets
• ·FCC partnership spans 20 years

30-03-2026

Alset Inc.'s majority-owned subsidiary, Alset International Limited, entered a securities purchase agreement with related party DSS Inc. on March 26, 2026, to provide a $2,450,000 loan in exchange for a 3% interest-bearing convertible promissory note (convertible at $0.74 per share) and warrants to purchase 16,554,055 shares of DSS common stock at $0.93 per share, both with 5-year terms. The transaction is contingent on DSS stockholder approval and was approved by Alset's Board and Audit Committee, with conflicted directors recused. No historical financial comparisons or performance metrics are disclosed.

• ·Closing contingent on DSS stockholder approval.
• ·Note and warrants mature/expire five years from issuance.
• ·Transaction approved by Alset's Board and Audit Committee; Chan Heng Fai and Chan Tung Moe recused from deliberations.

30-03-2026

Sysco Corporation ('Parent') has entered into an Agreement and Plan of Merger dated March 30, 2026, to acquire JRD Unico, Inc. (Maverick OpCo) and Warehouse Realty, LLC (Maverick PropCo) through a series of mergers involving New Slider Holdco, Inc. and wholly-owned merger subsidiaries, structured as a Parent Merger followed by OpCo and PropCo Mergers. The transaction has been unanimously approved by the boards of all relevant entities and is intended to qualify as tax-free reorganizations under Sections 368(a) and 351(a) of the Internal Revenue Code. A Stockholders Agreement and Letter Agreements will become effective upon closing, with no specific financial terms disclosed in the filing.

• ·Transaction structured under DGCL and DLLCA, with HSR Clearance and Form S-4 filing as closing conditions.
• ·Holder Representative (Ki Atlantic Holdings Limited) obtained Maverick OpCo Holder Approval and Maverick PropCo Holder Approval within 24 hours of execution.
• ·Exhibits include Stockholders Agreement (Exhibit A), Letter Agreements (Exhibit B), and Balance Sheet Rules (Exhibit C).

30-03-2026

Greenlane Holdings, Inc. received a Nasdaq notification letter on March 25, 2026, indicating failure to satisfy the $1.00 minimum bid price rule (Nasdaq Listing Rule 5550(a)(2)) over 30 consecutive business days from February 10 to March 24, 2026. Due to prior reverse stock splits—a 1-for-11 on August 5, 2024, and 1-for-750 on June 27, 2025, resulting in a cumulative 1-for-8,250 ratio—the company is ineligible for a 180-day compliance period. The company plans to request a hearing by April 1, 2026, to appeal, staying delisting pending the Panel's decision, though success is uncertain.

• ·Nasdaq Listing Rule 5810(c)(3)(A)(iv) denies compliance period due to reverse splits with cumulative ratio of 250:1 or more over prior two years.
• ·Company effected 1-for-11 reverse stock split on August 5, 2024, and 1-for-750 on June 27, 2025.
• ·Timely hearing request by April 1, 2026, automatically stays delisting action.

30-03-2026

InMed Pharmaceuticals Inc. received a Nasdaq notice on March 27, 2026, indicating its common shares' closing bid price fell below the $1.00 minimum for 30 consecutive trading days from February 11 to March 26, 2026, violating Listing Rule 5550(a)(2). The company has 180 calendar days to regain compliance with no immediate trading suspension, and may qualify for an additional 180 days if it meets other criteria, though success is not assured. InMed intends to monitor its share price and explore options like a reverse stock split to cure the deficiency.

• ·Shares continue to trade on The Nasdaq Capital Market under symbol 'INM' with no immediate delisting impact.
• ·If non-compliant after grace periods, Nasdaq may delist shares; company can appeal to a Hearings Panel, but trading would be suspended pending appeal.
• ·Press release announcing the notice attached as Exhibit 99.1.

30-03-2026

Skillsoft Corp. received a notice from the NYSE on March 26, 2026, stating it is not in compliance with Section 802.01B due to its 30 trading-day average market capitalization as of March 25, 2026, and stockholders' equity as of October 31, 2025, both being less than $50 million. While the company has an 18-month cure period, subject to NYSE approval of its business plan to be submitted within 45 days, and its Class A common stock (SKIL) will continue trading on the NYSE during this time, the noncompliance highlights significant financial weaknesses.

• ·NYSE Section 802.01B noncompliance
• ·Business plan submission within 45 calendar days from March 26, 2026
• ·Subject to quarterly NYSE review during cure period
• ·Press release dated March 30, 2026 (Exhibit 99.1)

30-03-2026

BullFrog AI Holdings, Inc. announced a commercial agreement with a top 5 global pharmaceutical company (by 2025 revenue) to apply its proprietary bfLEAP® platform for identifying and prioritizing novel drug targets in major depressive disorder (MDD), providing exclusive access to a target candidate. The agreement validates BullFrog AI’s AI capabilities in accelerating drug discovery. The MDD market exceeded $8 billion in 2025 and is projected to grow at nearly 5% annually to over $11 billion by 2032.

• ·MDD ranked as third cause of global disease burden in 2008 by WHO, projected to rank first by 2030
• ·Agreement announced March 30, 2026

30-03-2026

Advanced Flower Capital Inc. (AFC) expanded its senior secured revolving credit facility to $80 million with an additional $30 million commitment from its existing FDIC-insured Lead Arranger bank, which has over $75 billion in assets. The facility remains expandable to $100 million subject to lender participation. AFC intends to use the availability for funding existing borrower commitments, originating and participating in commercial loans to U.S. lower middle-market companies, and general corporate purposes.

• ·AFC is a publicly traded business development company (BDC) headquartered in West Palm Beach, Florida.
• ·Investor Relations Contact: Robyn Tannenbaum, 561-510-2293, ir@advancedflowercapital.com.
• ·Website: advancedflowercapital.com

30-03-2026

Twin Hospitality Group Inc., jointly administered in FAT Brands Inc.'s Chapter 11 bankruptcy filed January 26, 2026, reached an Amended and Restated Stipulation and Agreed Order via mediation, resolving disputes over cash collateral, trustee appointment, and executive suspension. The agreement mandates resignation of all non-Special Committee directors, vesting sole control in Special Committees and a New Chapter 11 CEO, while providing $5 million in Governance Agreement Payments to outgoing Executive Andrew Wiederhorn and terminating his and his family members' employment/roles with a 'walled off' leave of absence permitting asset bids. No operational improvements or financial recoveries are detailed, highlighting ongoing distress amid governance overhaul.

• ·Chapter 11 Cases commenced January 26, 2026 (Case No. 26-90126) in U.S. Bankruptcy Court, Southern District of Texas, Houston Division.
• ·Mediation termination dates extended to March 24, 2026.
• ·All prior agreements with Executive terminated effective Settlement Effective Date, except indemnification rights.
• ·Executive Family Members' accrued compensation paid through termination date.
• ·Director Fees for non-Special Committee board members payable only upon Resignation, covering through March 31, 2026.

30-03-2026

Weave Communications, Inc. appointed Ryan Dubin and Edward Robson as new independent directors effective immediately and entered into a cooperation agreement with activist investors Engine Capital and 2717 Partners. The Board will form a new Finance Committee chaired by David Silverman, including the new directors, and initiate a search for a third independent director with software operating experience. Company leadership highlighted recent consistent top-line growth, expanding margins, and disciplined cash generation, positioning Weave to drive long-term shareholder value.

• ·Ryan Dubin appointed to Audit and Finance Committees; Edward Robson to Nominating and Governance and Finance Committees.
• ·Messrs. Dubin and Robson appointed as Class III directors; third director to be Class II.
• ·Advisors: Jefferies LLC (financial), Orrick, Herrington & Sutcliffe LLP (legal) for Weave; Olshan Frome Wolosky LLP for Engine Capital and 2717.
• ·Cooperation agreement includes customary standstill, voting, and committee rights; to be filed on Form 8-K.
• ·Risks include integration of TrueLark acquisition and macroeconomic uncertainties.

30-03-2026

Willis Lease Finance Corporation (WLFC) amended and extended its revolving credit facility, increasing total commitments from $1.0 billion to $1.75 billion and extending maturity to April 2031. The amendment was oversubscribed with approximately $1.0 billion in excess lender commitments, signaling strong market confidence in the company's platform. EVP & CFO Scott B. Flaherty noted that the enhanced capacity will support continued growth and diversification.

• ·Announcement date: March 30, 2026
• ·New facility maturity: April 2031

30-03-2026

RenX Enterprises Corp. amended its Amended and Restated Certificate of Incorporation to effect a 1-for-20 reverse stock split of its Common Stock (par value $0.001 per share), approved by the Board and stockholders, effective at 12:01 a.m. Eastern Time on March 26, 2026. No fractional shares will be issued; holders will receive cash in lieu based on the average closing sales price on Nasdaq Capital Market for the 10 days preceding effectiveness. This filing by Safe & Green Development Corp (SGD) includes the certificate as Exhibit 3.1.

• ·Reverse split combines every 20 pre-split shares into 1 post-split share.
• ·Certificate signed by CEO on March 25, 2026.
• ·Filed under Items 3.03, 5.03, 8.01, 9.01 of Form 8-K on March 30, 2026.

30-03-2026

Lakeland Industries, Inc. completed the sale of its High Performance Flame Resistant (HPFR) and High-Visibility (HiViz) product lines to National Safety Apparel on March 30, 2026, strengthening its balance sheet and enhancing capital flexibility for investments. This divestiture streamlines the portfolio to focus on fire services growth through acquisitions and organic investments, as well as core industrial PPE markets. Lakeland will provide transitional support via a services agreement to ensure customer continuity.

• ·Filing date: March 30, 2026
• ·Advisors: Cherry Tree & Associates (financial), Maynard Nexsen (legal)

30-03-2026

Quince Therapeutics, Inc. (Nasdaq: QNCX) settled approximately $16.4 million of outstanding debt obligations to the European Investment Bank (EIB) for a one-time payment of $5.5 million, effective immediately upon payment on March 30, 2026. This fully discharges all obligations under the loan and settlement agreements, removing a substantial overhang that constrained strategic flexibility. The company is advancing its corporate restructuring and evaluation of strategic alternatives, such as merger, reverse merger, or asset sale, to maximize shareholder value.

• ·Debt obligations measured as of March 27, 2026
• ·Strategic alternatives include merger, reverse merger, asset sale, or other strategic transactions